Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis expands R&D in China

Sanofi-aventis has announced the establishment of a biometrics centre in Beijing as part of the expansion of its R&D facilities in China

Sanofi-aventis has announced the establishment of a biometrics centre in Beijing as part of the expansion of its R&D facilities in China.

The state-of-the-art centre will specialise in the design, data management and analysis of global and local trials, in both pharmaceuticals and vaccines development, through all four phases.

The French firm's partnership agreement with the Shanghai Institutes for Biological Sciences (SIBS) plays a key role in strengthening the company's R&D facilities. This partnership, which is part of the China Discovery platform set up by sanofi-aventis to build relationships with top Chinese academic institutions, aims to identify innovative, first-in-class drugs.

"This collaboration agreement brings pharmaceutical R&D in China to another level, by allowing talented Chinese scientists to become internationally recognised and ensuring that discoveries made in the area of basic research are rapidly converted into applications for treating diseases," said Dr Jia-Rui Wu, vice president of the SIBS.

Sanofi-aventis has also launched a scholarship programme in China to recognise promising scientists engaged in cutting-edge pharmaceutical R&D.

21st October 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics